Showing 5811-5820 of 5956 results for "".
- Ivantis Receives FDA Approval for the Hydrus Microstent for Minimally Invasive Glaucoma Surgery (MIGS)https://modernod.com/news/ivantis-receives-fda-approval-for-the-hydrus-microstent-device-for-minimally-invasive-glaucoma-surgery-migs/2479950/Ivantis announced that it has received FDA approval for the Hydrus Microstent, a microinvasive glaucoma surgery (MIGS) device used to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery. “The Hydrus represents a unique next-generation
- Australian Research Lifts the Lid on Lipids to Prevent Dry Eyehttps://modernod.com/news/australian-research-lifts-the-lid-on-lipids-to-prevent-dry-eye/2479951/Australian researchers have made an important breakthrough in understanding the composition of the tear film that protects the eyes, leading to more effective treatments for dry eye disease. The project was a collaboration between researchers at University of Wollongong, QUT and the Univ
- Eye Health America Acquires Montgomery & Riddle Eyecare and The Surgery and Laser Center at Professional Parkhttps://modernod.com/news/eye-health-america-acquires-montgomery-riddle-eyecare-in-south-carolina/2479957/Eye Health America (EHA) announced its acquisition of Montgomery & Riddle Eyecare and The Surgery & Laser Center at Professional Park, an eye care provider in South Carolina. Terms of the deal were not disclosed. The acquisition of Montgomery & Riddle Eyecare strengthens
- Ocutech Introduces New Ves Falcon Autofocus Bioptic Telescopehttps://modernod.com/news/ocutech-introduces-new-ves-falcon-autofocus-bioptic-telescope/2479963/Following 6 years of development and testing, Ocutech has introduced its new VES Falcon Autofocus Bioptic Telescope, the company’s next generation autofocusing bioptic for the visually impaired. The Falcon is in initial limited release with select low-vision specialists in the United
- International Sports Vision Association Announces Appointment of Gary Esterow as Executive Directorhttps://modernod.com/news/international-sports-vision-association-announces-appointment-of-gary-esterow-as-executive-director/2479964/The International Sports Vision Association (ISVA), an organization of optometrists, athletic trainers, therapists, physicians and sports teams dedicated to evaluating, training, and improving vision performance in athletes, announced the appointment of Gary Esterow as Executive Director.
- Imprimis Announces Clinical Trial for Dropless TriMoxi Formulation in Canadahttps://modernod.com/news/imprimis-announces-clinical-trial-for-dropless-trimoxi-formulation-in-canada/2479968/Imprimis Pharmaceuticals announced that its Canadian partner, Advanced Dosage Forms, will begin enrolling patients at McGill University Health Centre (MUHC) for a clinical trial of Imprimis’s leading Dropless (triamcinolone acetonide-moxifloxacin) formulation aft
- EyePoint Pharmaceuticals Appoints David Price as Chief Financial Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-david-price-as-chief-financial-officer/2479969/EyePoint Pharmaceuticals announced the appointment of David Price as Chief Financial Officer, effective immediately. In this role, Mr. Price will oversee and lead the company’s financial and capital markets activities. Mr. Price brings to EyePoint more than 25 years of financial experience
- Thomas Burns, CEO of Glaukos, Joins Avedro’s Board of Directorshttps://modernod.com/news/thomas-burns-ceo-of-glaukos-joins-avedros-board-of-directors/2479974/Avedro announced that Thomas W. Burns has been elected to its board of directors. Mr. Burns has a proven track record of building successful medical device and pharmaceutical businesses and creating successful new markets in ophthalmology. Mr. Burns is President, Chief Executive Officer and a mem
- Aussie Researchers Identify New Genetic Markers for Glaucomahttps://modernod.com/news/aussie-researchers-identify-new-genetic-markers-for-glaucoma/2479975/Australian researchers said they have identified 40 new genetic markers that increase a person’s risk of developing glaucoma, pointing to improvements in testing and predicting the risks of getting the eye disease, according to a
- Data from BioTime’s OpRegen Program to Be Presented at AAO 2018https://modernod.com/news/data-from-biotimes-opregen-program-to-be-presented-at-aao-2018/2479983/BioTime announced that its abstract “PI/IIa Study of Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry-Form AMD Patients,” has been accepted for an oral presentation at the upcoming American Academy of Ophthalmology (AAO) meeting taking place from October 27-30